NKG2D blockade attenuated cardiac allograft vasculopathy in a mouse model of cardiac transplantation

Clinical and Experimental Immunology

Volumn 173, Issue 3, 2013, Pages 544-552

  Chen, H ^a   Xia, J ^a   Zhang, L ^a   Jin, X ^a   Yang, M ^a   Li, J ^b   Zhao, Y ^a  

^a WUHAN UNIVERSITY   (China)

^b Wuhan Central Hospital   (China)

Author keywords

Cardiac allograft vasculopathy; IL 17; IL 6; NKG2D; Regulatory T cell

Indexed keywords

ABATACEPT; ALLOANTIBODY; INTERLEUKIN 17; INTERLEUKIN 6; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; NKG2D MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

CARDIAC ALLOGRAFT VASCULOPATHY; IL-17; IL-6; NKG2D; REGULATORY T CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; GENE EXPRESSION; GRAFT SURVIVAL; HEART TRANSPLANTATION; INTERLEUKIN-6; ISOANTIBODIES; LEUKOCYTES; MALE; MICE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS; VASCULAR DISEASES;

EID: 84881535781     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12128     Document Type: Article

References (47)

1. Weis M, von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 1997; 96:2069-2077.
2. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA-4-Ig. Transplantation 1994; 57:1701-1706.
3. Larsen CP, Elwood ET, Alexander DZ etal. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381:434-438.
4. Turka LA, Linsley PS, Lin H etal. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89:11102-11105.
5. Sayegh MH, Akalin E, Hancock WW etal. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181:1869-1874.
6. Van Belle TL, Ling E, Haase C, Bresson D, Urso B, von Herrath MG. NKG2D blockade facilitates diabetes prevention by antigen-specific Tregs in a virus-induced model of diabetes. J Autoimmun 2013; 40:66-73.
7. Diefenbach A, Tomasello E, Lucas M etal. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 2002; 3:1142-1149.
8. Kjellev S, Haase C, Lundsgaard D, Urso B, Tornehave D, Markholst H. Inhibition of NKG2D receptor function by antibody therapy attenuates transfer-induced colitis in SCID mice. Eur J Immunol 2007; 37:1397-1406.
9. Hirohashi T, Chase CM, Della PP etal. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12:313-321.
10. Millington TM, Madsen JC. Innate immunity and cardiac allograft rejection. Kidney Int Suppl 2010; 119:S18-21.
11. Schiechl G, Brunner SM, Kesselring R etal. Inhibition of innate co-receptor TREM-1 signaling reduces CD4 T cell activation and prolongs cardiac allograft survival. Am J Transplant 2013; 13:1168-1180.
12. Wang S, Xu X, Xie A etal. Anti-interleukin-12/23p40 antibody attenuates chronic rejection of cardiac allografts partly via inhibition gammadeltaT cells. Clin Exp Immunol 2012; 169:320-329.
13. Zou Y, Stastny P, Susal C, Dohler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357:1293-1300.
14. Raulet DH. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 2004; 5:996-1002.
15. Karimi M, Cao TM, Baker JA, Verneris MR, Soares L, Negrin RS. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol 2005; 175:7819-7828.
16. Kim J, Chang CK, Hayden T etal. The activating immunoreceptor NKG2D and its ligands are involved in allograft transplant rejection. J Immunol 2007; 179:6416-6420.
17. Li J, Zhu H, Wang S etal. Blockade of NKG2D synergized with CTLA-4-Ig in promoting long-term graft survival in murine models of cardiac transplantation. Transplantation 2012; 93:356-363.
18. Ito Y, Kanai T, Totsuka T etal. Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol 2008; 294:G199-207.
19. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16:343-350.
20. Itoh S, Kimura N, Axtell RC etal. Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion. Circulation 2011; 124:S187-196.
21. Ke Y, Liu K, Huang GQ etal. Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. J Immunol 2009; 182:3183-3190.
22. Holschermann H, Bohle RM, Zeller H etal. In situ detection of tissue factor within the coronary intima in rat cardiac allograft vasculopathy. Am J Pathol 1999; 154:211-220.
23. Li J, Xia J, Zhang K, Xu L. Suppression of acute and chronic cardiac allograft rejection in mice by inhibition of chemokine receptor 5 in combination with cyclosporine A. J Surg Res 2009; 157:81-90.
24. Li J, Chen G, Ye P etal. CCR5 blockade in combination with cyclosporine increased cardiac graft survival and generated alternatively activated macrophages in primates. J Immunol 2011; 186:3753-3761.
25. Chen X, Das R, Komorowski R etal. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009; 114:891-900.
26. Gorbacheva V, Fan R, Li X, Valujskikh A. Interleukin-17 promotes early allograft inflammation. Am J Pathol 2010; 177:1265-1273.
27. Tavares AM, Da RAA, Baldo G etal. Bone marrow derived cells decrease inflammation but not oxidative stress in an experimental model of acute myocardial infarction. Life Sci 2010; 87:699-706.
28. Azimzadeh AM, Pfeiffer S, Wu GS etal. Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates. Am J Transplant 2005; 5:2349-2359.
29. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8:942-949.
30. Kopf M, Baumann H, Freer G etal. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368:339-342.
31. Schnickel GT, Bastani S, Hsieh GR etal. Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection. J Immunol 2008; 180:4714-4721.
32. Magil AB. Monocytes/macrophages in renal allograft rejection. Transplant Rev (Orlando) 2009; 23:199-208.
33. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol 2005; 23:901-944.
34. Wyburn KR, Jose MD, Wu H, Atkins RC, Chadban SJ. The role of macrophages in allograft rejection. Transplantation 2005; 80:1641-1647.
35. Bohmig GA, Exner M, Habicht A etal. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13:1091-1099.
36. Behr TM, Feucht HE, Richter K etal. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant 1999; 18:904-912.
37. Poelzl G, Ullrich R, Huber A etal. Capillary deposition of the complement fragment C4d in cardiac allograft biopsies is associated with allograft vasculopathy. Transpl Int 2005; 18:313-317.
38. Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol 2004; 19:166-169.
39. Ratliff NB, McMahon JT. Activation of intravascular macrophages within myocardial small vessels is a feature of acute vascular rejection in human heart transplants. J Heart Lung Transplant 1995; 14:338-345.
40. Itoh S, Nakae S, Axtell RC etal. IL-17 contributes to the development of chronic rejection in a murine heart transplant model. J Clin Immunol 2010; 30:235-240.
41. Serada S, Fujimoto M, Mihara M etal. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2008; 105:9041-9046.
42. Fujimoto M, Nakano M, Terabe F etal. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol 2011; 186:32-40.
43. Groux H, O'Garra A, Bigler M etal. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-742.
44. Itoh M, Takahashi T, Sakaguchi N etal. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999; 162:5317-5326.
45. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3:199-210.
46. Roy S, Barnes PF, Garg A, Wu S, Cosman D, Vankayalapati R. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J Immunol 2008; 180:1729-1736.
47. Ogasawara K, Hamerman JA, Ehrlich LR etal. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 2004; 20:757-767.